Very recently, the third-generation TKI inhibitor osimertinib has been approved to effectively target to EGFR T790M mutation with a response rate of 61% in NSCLC, significantly extending the overall survival in patients with the T790M mutation (9). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.